Infectious complications of bispecific antibody therapy in patients with multiple myeloma
Open accessAbstract
Infection has a significant impact on patients with multiple myeloma (MM) [ 1 ]. Bispecific antibody (BsAb) therapy with multiple targets (BCMA, GPRC5D and FCRH5) is increasingly used with good disease response rates [ 2 ]. Trial data on infections has been limited, with incidences of all-grade infections reported at 13–76% and grade ≥3 at 3–45% [ 3 , 4 ]. However, the diagnostic criteria used and infection episodes were not well characterised. Therefore this study was conducted to describe the epidemiology and outcomes of infections in BsAb treated MM patients to better guide antimicrobial prophylaxis and treatment in this emerging cohort.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
BCMA-targeted T-cell-redirecting therapies have been linked to a heightened susceptibility to infectious complications due to their mechanism of action.
“BCMA-targeted T-cell-redirecting therapies have been linked to a heightened susceptibility to infectious complications due to their mechanism of action30–33.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [30]
The Discussion reports substantial infection rates in trials of T-cell/BCMA-targeting bispecific antibodies, supporting the link to infectious complications. It does not establish that their mechanism of action causes heightened susceptibility; the authors also note that infection rates in their heavily treated cohort were comparable to those with other therapies. No page number is available in our copy. (LLM, conf=0.84)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Anti–B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma
Topp, M. S., Duell, J., Zugmaier, G., Attal, M., Moreau, P., Langer, C., Krönke, J., Facon, T., Salnikov, A. V., Lesley, R., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02657 · Cited by 304 · see citing works
Lancman, G., Parsa, K., Kotlarz, K., Avery, L., Lurie, A., Lieberman-Cribbin, A., Cho, H. J., Parekh, S. S., Richard, S., Richter, J., et al. (2023) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-23-0049 · Cited by 140 · see citing works
Flagged first, then by citations
Research works printed but not linked: 13
- [1]Johnsrud AJ Johnsrud JJ Susanibar SA Kamimoto JJ Kothari A Burgess M Infectious and immunological sequelae of daratumumab in multiple myeloma Br J Haematol 2019 185 187 9 10.1111/bjh.15433 29974956 · DOI
- [2]Lancman G Sastow DL Cho HJ Jagannath S Madduri D Parekh SS Bispecific antibodies in multiple myeloma: present and future Blood Cancer Discov 2021 2 423 33 10.1158/2643-3230.BCD-21-0028 34661161 PMC8510808 · DOI
- [3]Kazandjian D, Kowalski A, Landgren O. T cell redirecting bispecific antibodies for multiple myeloma: emerging therapeutic strategies in a changing treatment landscape. Leukemia Lymphoma. 2022;63:3032–43. PMC10113039 36059239
- [4]Costa LJ Wong SW Bermúdez A de la Rubia J Mateos M-V Ocio EM First Clinical Study of the B-cell maturation antigen (BCMA) 2+1 T cell engager (TCE) CC-93269 in patients (Pts) with relapsed/refractory multiple myeloma (RRMM): interim results of a phase 1 multicenter trial Blood 2019 134 143 10.1182/blood-2019-122895 · DOI
- [5]Lee DW Santomasso BD Locke FL Ghobadi A Turtle CJ Brudno JN ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells Biol Blood Marrow Transplant 2019 25 625 38 10.1016/j.bbmt.2018.12.758 30592986 PMC12180426 · DOI · Paper page
- [7]Pizzo PA Armstrong D Bodey G Pauw BD Feld R Glauser M From the immunocompromised host society: the design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient: report of a consensus panel J Infect Dis 1990 161 397 401 10.1093/infdis/161.3.397 2179421 · DOI
- [8]D’Souza A Shah N Rodriguez C Voorhees PM Weisel K Bueno OF A phase I first-in-human study of ABBV-383, a B-cell maturation antigen × CD3 bispecific T-cell redirecting antibody, in patients with relapsed/refractory multiple myeloma J Clin Oncol 2022 40 3576 86 10.1200/JCO.22.01504 36029527 PMC9622641 · DOI
- [9]Plesner T Harrison SJ Quach H Lee CH Bryant A Vangsted AJ A phase I study of RO7297089, a B-cell maturation antigen (BCMA)-CD16a bispecific antibody in patients with relapsed/refractory multiple myeloma (RRMM) Blood 2021 138 2755 10.1182/blood-2021-147418 · DOI
- [10]Hammons LR Szabo A Janardan A Dhakal B Chhabra S D’Souza A Kinetics of humoral immunodeficiency with bispecific antibody therapy in relapsed refractory multiple myeloma JAMA Netw Open 2022 5 e2238961 10.1001/jamanetworkopen.2022.38961 36306135 PMC9617177 · DOI
- [11]Lancman G Parsa K Rodriguez C Richter J Cho HJ Parekh S Infections and severe hypogammaglobulinemia in multiple myeloma patients treated with anti-BCMA bispecific antibodies Blood 2022 140 10073 4 10.1182/blood-2022-163733 PMC10618720 37769148 · DOI
- [12]Lim C Sinha P Harrison SJ Quach H Slavin MA Teh BW Epidemiology and risks of infections in patients with multiple myeloma managed with new generation therapies Clin Lymphoma Myeloma Leuk 2021 21 444 50.e443 10.1016/j.clml.2021.02.002 33722538 · DOI
- [13]Cooper D Madduri D Lentzsch S Jagannath S Li J Boyapati A Safety and preliminary clinical activity of REGN5458, an anti-Bcma x anti-CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma Blood 2019 134 3176 10.1182/blood-2019-126818 · DOI
- [15]Lim C Sinha P Harrison SJ Quach H Slavin MA Teh BW Low rates of invasive fungal disease in patients with multiple myeloma managed with new generation therapies: results from a multi-centre cohort study Mycoses 2021 64 30 34 10.1111/myc.13178 32885525 · DOI
Cited by
Sorted by citations
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
Lesokhin, A. M., Tomasson, M. H., Arnulf, B., Bahlis, N. J., Miles Prince, H., Niesvizky, R., Rodrίguez-Otero, P., Martinez-Lopez, J., Koehne, G., Touzeau, C., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02528-9 · Cited by 664 · see citing works
GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review
Rodriguez-Otero, P., van de Donk, N. W. C. J., Pillarisetti, K., Cornax, I., Vishwamitra, D., Gray, K., Hilder, B., Tolbert, J., Renaud, T., Masterson, T., et al. (2024) · Blood Cancer Journal · doi:10.1038/s41408-023-00966-9 · Cited by 113 · see citing works
- Authors
- Sim, B. Z., Longhitano, A., Er, J., Harrison, S. J., Slavin, M. A., & Teh, B. W.
- Affiliations
- The University of Melbourne (AU)
- Peter MacCallum Cancer Centre (AU)
- The Royal Melbourne Hospital (AU)
- Corresponding author
- Sim, Beatrice Z.
- ORCID
- Venue
- Blood Cancer Journal
- Published
- 2023-03-10
- Volume
- 13
- Issue
- 1
- Pages
- 34-34
- ISSN
- 2044-5385 (ISSN-L)
- PMC
- PMC9998258
- OpenAlex
- W4323811721
- Cited by
- 50
- References
- 2
- Citations by year
- 2026: 13 · 2025: 8 · 2024: 19 · 2023: 10
- FWCI
- 10.33
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Blood Cancer Journal (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Australian Government
- Medical Research Future Fund
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Oncology › Neutropenia and Cancer Infections
- Keywords
- multiple myeloma, bispecific antibodies, infection, BCMA, GPRC5D, FcRH5, infectious disease epidemiology, antibiotic prophylaxis, treatment outcomes
- MeSH terms
- Humans, Multiple Myeloma, Antibodies, Bispecific, Cell Line, Tumor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
